nintedanib (Avalyn Pharma)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug Namenintedanib (Avalyn Pharma)

Drug Alias NameAP-02 (Avalyn Pharma)nintedanib (Avalyn Pharma)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor subunit A inhibitorsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 3 antagonists +[8]

TargetsVascular endothelial growth factor receptor 1Platelet-derived growth factor receptor betaFibroblast growth factor receptor 1 +[8]

Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPulmonary Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAvalyn Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesAvalyn Pharma Inc

Inactive CompaniesN/A

Active IndicationsIdiopathic Pulmonary FibrosisPulmonary Fibrosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A